Aureka is developing a potentially best-in-class dual-specific ActRIIA/ActRIIB antibody for the treatment of heart failure (HF), obesity, and other cardiometabolic diseases.

Disease rationale: Dysregulated activin receptor signaling contributes to pathological cardiac remodeling, pulmonary vascular dysfunction, and skeletal muscle wasting, driving disease progression and reduced functional capacity in HF.

Dual mechanism: Simultaneous blockade of ActRIIA and ActRIIB aims to suppress pathogenic activin/myostatin signaling, potentially improving cardiac function, preserving skeletal muscle mass, and enhancing functional capacity.

Differentiation: By targeting complementary cardiac and skeletal muscle pathways, dual ActRIIA/ActRIIB blockade offers a differentiated approach beyond conventional neurohormonal and hemodynamic therapies.

Unmet need: Despite advances in standard-of-care (SOC) therapies, substantial residual morbidity and functional impairment remain in HF, supporting the need for therapies addressing underlying disease biology.

Aureka is developing a dual-specific Activin A × GDF8 antibody for the treatment of pulmonary arterial hypertension (PAH) and Group 2 pulmonary hypertension (PH).

Disease rationale: Dysregulated activin/GDF signaling contributes to pathological pulmonary vascular remodeling, increased pulmonary vascular resistance, and progressive right-ventricular dysfunction.

Dual mechanism: Simultaneous Activin A/GDF8 blockade aims to suppress pathological pulmonary vascular remodeling while preserving skeletal muscle mass and function, potentially improving both cardiopulmonary health and exercise capacity.

Differentiation: Targeting complementary vascular and skeletal muscle pathways offers the potential for broader functional benefits beyond pulmonary hemodynamic improvement alone. Precision antibody engineering with improved ligand selectivity potentially offers optimal safety profiles compared to ligand traps.

Unmet need: Despite advances in vasodilator and activin-pathway therapies, PAH remains a progressive disease with substantial residual morbidity and mortality, highlighting the need for differentiated therapies that provide durable clinical and functional benefits.

Aureka is developing a potentially first-in-class LAG-3 × PD-1 bispecific antibody for the treatment of autoimmune diseases.

Dual PD-1/LAG-3 targeting aims to restore immune homeostasis and peripheral tolerance through complementary checkpoint agonism and Fc-mediated depletion of pathogenic T cells.

Significant unmet need remains in T-cell–dominant autoimmune diseases, where current therapies often provide incomplete or transient disease control and do not directly eliminate disease-driving T-cell populations.

The IL-11 program leverages epitope-specific, affinity-matured antibody engineering to deliver best-in-class potential, targeting a key pathway linking inflammation, tissue remodeling, and fibrosis.

Bispecific antibodies combining IL-11 blockade with complementary anti-inflammatory mechanisms offer a differentiated strategy to go beyond the efficacy of current biologics by simultaneously addressing the inflammatory drivers of disease and the downstream tissue remodeling and fibrosis that contribute to disease progression.

Aureka is developing next generation brain and tissue shuttles to deliver RNAs and biologics to treat a variety of CNS and aging-related diseases.